[Ip-health] InPharm: Novartis Indian patent battle nears conclusion

Joanna Keenan-Siciliano joanna.l.keenan at gmail.com
Thu Mar 8 03:33:58 PST 2012


InPharm
Novartis Indian patent battle nears conclusion

A long-running battle over the patent of cancer treatment Glivec in India
is about to reach its dramatic climax.
http://www.inpharm.com/news/171663/novartis-indian-patent-battle-nears-conclusion

India’s Supreme Court will shortly make a ruling which could end a six-year
legal battle between Novartis and the Indian government, and could be
decisive for the future of patents in the country.

The Swiss pharma company began its legal action after its patent
application for leukaemia drug Glivec was rejected in 2006.

Novartis maintains that Section 3(d) of Indian patent law does not comply
with international patent law, but it has twice had its case rejected by
Indian courts.

Non-governmental organisations such as Medecins Sans Frontieres have
opposed Novartis throughout the period, saying a victory for the company
would affect India’s entire generic industry.

MSF says poorer countries rely on India’s generics firms to product
low-cost medicines, and without them, the health of millions could suffer.

The company said in a statement that it believed that using India’s legal
system was a ‘legitimate and appropriate approach’ to gaining clarity on
India’s patent law.

“We need to know if we can rely on patents in India and whether as a
research-based organisation we can continue to invest in the development of
better medicines for India”.

Novartis also says it disagrees with MSF and other activist groups that the
challenge threatens availability of all generics. “The basis of this
argument is false and very misleading,” it said.

The company notes that generic drugs launched in India before 2005 -
including HIV/AIDS medicines and generic versions of Glivec will still be
available in the country regardless of the Supreme Court’s ruling.

India updated its patent laws in 2005 to bring them into line with
international standards, but has allowed generics already on the market to
remain.

Novartis insists that it supports ‘flexibilities’ in the international
trade agreements that allow countries like India to make exceptions to
patent rights, such as when a national public health crisis requires
supplies of cheap medicines.

The company says it runs various projects to ensure access for its drugs in
poorer countries. Its Glivec International Patient Assistance Programme has
helped more than 31,000 patients in 2011, and Novartis currently provides
the drug free of charge to around 15,000 patients in India - more than 95%
of those receiving the medicine.

India’s generic firms are a powerful lobby in the country, and a leading
industry which politicians want to nurture. This means that whatever the
outcome, the Indian government is likely to ensure that the generics sector
will continue operating.

Joanna Keenan
Press Officer
Médecins Sans Frontières - Access Campaign
E: joanna.keenan[at]geneva.msf.org
T: twitter.com/joanna_keenan

msfaccess.org
twitter.com/MSF_access
facebook.com/MSFaccess



More information about the Ip-health mailing list